X-Linked Juvenile Retinoschisis

Nearly all patients with XLRS develop foveal schisis, which is the splitting of retinal layers in the macula, the central part of the retina responsible for sharp, detailed vision. This creates small cyst-like spaces within the retina that interfere with clear central vision. Foveal schisis is the primary reason most patients experience reduced visual acuity, and it is often the first finding that leads to diagnosis. The pattern of cystic changes in the fovea can resemble cystoid macular edema, which is why specialized imaging is essential for an accurate diagnosis.

Approximately half of XLRS patients also develop peripheral schisis, where the splitting occurs in the outer regions of the retina. Peripheral schisis increases the risk of complications such as retinal tears, retinal detachment, and vitreous hemorrhage, which is bleeding into the gel-like substance that fills the eye. Patients with peripheral involvement may notice sudden floaters or flashes of light, which should be evaluated promptly by a retina specialist.

XLRS tends to cause relatively stable, moderately reduced vision through much of childhood and early adulthood. Visual acuity typically ranges from 20/40 to 20/100 in many patients, though some individuals have milder or more severe impairment. Vision may gradually decline in later decades as the retina undergoes slow degenerative changes, and some patients develop macular atrophy over time.

Most patients with XLRS maintain useful vision throughout childhood and into adulthood, though visual acuity is typically reduced compared to normal. Gradual decline can occur in later decades due to progressive macular atrophy. Serious complications such as retinal detachment or large vitreous hemorrhage can cause more significant vision loss if not treated promptly, which is why regular monitoring with our retina specialists is essential.

If there is a family history of XLRS, we recommend a dilated retinal examination as early as infancy. Many cases are diagnosed between the ages of five and ten when reduced vision first becomes noticeable. Early diagnosis allows us to begin monitoring, initiate treatment when appropriate, and help families plan for educational and developmental support.

Gene therapy for XLRS is currently available only through clinical trials. The most advanced program, ATSN-201, has shown positive results in its Phase 1/2 LIGHTHOUSE trial, with structural improvements and vision gains in treated patients aged six years and older. We can help families determine whether their child may be eligible for current or upcoming clinical trials and provide referrals when appropriate.

Unlike conditions such as retinitis pigmentosa, which primarily affects the photoreceptor cells and peripheral vision first, XLRS targets the structural integrity of the retinal layers, with the central macula most commonly involved. XLRS specifically results from a deficiency of the retinoschisin protein rather than a photoreceptor degeneration. The characteristic spoke-wheel foveal cyst pattern and electronegative ERG help our retina specialists distinguish XLRS from conditions with overlapping features, such as central serous retinopathy or other causes of macular fluid.

Many physical activities are safe for children with XLRS, but high-impact contact sports such as boxing, martial arts, and tackle football carry additional risk due to the fragile nature of the split retina. We work with each family to develop guidelines that keep children active while minimizing the chance of retinal complications. Non-contact sports, swimming, and moderate exercise are generally well suited for most XLRS patients.

We typically recommend retinal examinations with OCT imaging every six to twelve months, depending on the severity of the condition and whether the child is using carbonic anhydrase inhibitor drops. More frequent visits may be needed if there are changes in vision, new symptoms like floaters or flashes, or if peripheral schisis requires closer monitoring.